Equity Overview
Price & Market Data
Price: $46.01
Daily Change: -$1.28 / 2.78%
Range: $46.01 - $47.33
Market Cap: $3,058,016,256
Volume: 470,115
Performance Metrics
1 Week: -1.39%
1 Month: 57.85%
3 Months: 36.63%
6 Months: 4.24%
1 Year: 35.84%
YTD: 16.73%
Company Details
Employees: 188
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.